Prescription medicine
Famotidine and ibuprofen First approved as Duexis
Famotidine and ibuprofen (Duexis) is a prescription medicine with an FDA approval on record since 2011. FDA's NDC Directory lists it from 16 generic labelers, and pharmacies paid $0.714 per unit (Ibuprofen-famotidin 800-26.6 mg) in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the famotidine and ibuprofen FDA label on DailyMed (effective July 3, 2025, Aurobindo Pharma Limited); the NDA 22519 record on Drugs@FDA; every famotidine and ibuprofen label on DailyMed.
Highlights of the record
FDA label of July 3, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS.
Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1) ]. Ibuprofen and famotidine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2) ]. WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. […]
Used for
From the label: indications and usageIbuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indicati
Forms and strengths
- 800 mg / 26.6 mg
Film-coated tablet; tablet.
On the market
- Earliest approval on file
- April 23, 2011 Duexis, Horizon; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 7 first August 3, 2021; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 16 of which 16 under generic applications, 0 under brand applications, repackagers included
- Last listed patent
- July 18, 2026 Duexis tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.714 per unit Ibuprofen-famotidin 800-26.6 mg
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2023 0 Class I among all firms' recalls; latest December 29, 2023
- FAERS reports
- 10 through July 30, 2026
What is famotidine and ibuprofen used for?
From the label: indications and usageIbuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies (14), Use in Specific Populations (8.5) ]. […]
Conditions named in the indications of famotidine and ibuprofen's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Histamine-2 Receptor Antagonist and Nonsteroidal Anti-inflammatory Drug.
Source: FDA drug label (Ibuprofen and famotidine), Aurobindo Pharma Limited, effective July 3, 2025 (SPL set 21688404-41fb-487e-8ba0-aea4431a42fa), via openFDA; the full label on DailyMed
What does the patient leaflet for famotidine and ibuprofen say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about ibuprofen and famotidine tablets?Ibuprofen and famotidine tablets can cause serious side effects including: Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: with increasing doses of medicine containing NSAIDs with longer use of medicine containing NSAIDs Do not take ibuprofen and famotidine tablets right before or after a heart surgery called a “coronary artery bypass graft (CABG).” Avoid taking ibuprofen and famotidine tablets after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take ibuprofen and famotidine tablets after a recent heart attack. Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: anytime during use without warning symptoms that may cause death The risk of getting an ulcer or bleeding increases with: past history of stomach ulcers, or stomach or intestinal bleeding with the use of NSAIDs smoking drinking alcohol taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs”, or “SNRIs” older age poor health increasing doses of NSAIDs advanced liver disease longer use of NSAIDs bleeding problems You should take ibuprofen and famotidine tablets exactly as prescribed, at the lowest dose possible and for the shortest time needed. Ibuprofen and famotidine tablet contains a non-steroidal anti-inflammatory drug NSAID (ibuprofen). Do not use ibuprofen and famotidine tablets with other medicines to lessen pain or fever or with other medicines for colds or sleeping problems without talking to your healthcare provider first, because they may contain an NSAID also. […]
Source: FDA drug label (Ibuprofen and famotidine), Aurobindo Pharma Limited, effective July 3, 2025 (SPL set 21688404-41fb-487e-8ba0-aea4431a42fa), via openFDA; the full label on DailyMed
Is there a generic for famotidine and ibuprofen (Duexis)?
The FDA approved the first generic famotidine and ibuprofen on August 3, 2021. 7 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists famotidine and ibuprofen from 16 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 5 patents for Duexis tablets, the last expiring on July 18, 2026. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2011 earliest approval on file
- 2021 first generic approved
- 2026 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for famotidine and ibuprofen (Duexis)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.714 per unit (Ibuprofen-famotidin 800-26.6 mg), down 22% from $0.914 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ibuprofen-famotidin 800-26.6 mg (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ibuprofen-famotidin 800-26.6 mg | Generic | $0.714 per unit | n/a | -22% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has famotidine and ibuprofen been recalled?
The FDA's Enforcement Report lists 1 recall naming famotidine and ibuprofen since 2023: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 29, 2023 | Class II | Ascend Laboratories, LLC | Presence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the famotidine and ibuprofen label say about other medicines?
The famotidine and ibuprofen label names 24 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | contraindications | History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. |
| Atazanavir | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … is dependent on gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Cyclosporine | drug interactions | Clinical Impact: Concomitant use of ibuprofen and cyclosporine may increase cyclosporine’s nephrotoxicity. Intervention: During concomitant use of ibuprofen and famotidine and cyclosporine, monitor patients for signs of worsening renal function. NSAIDs and Salicylates |
| Dasatinib | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. Intervention: Concomitant administration of ibuprofen and famotidine is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. … |
| Diclofenac | drug interactions | NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. |
| Diflunisal | drug interactions | NSAIDs and Salicylates Clinical Impact: Concomitant use of ibuprofen with other NSAIDs or salicylates (…) increases the risk of GI toxicity, with little or no increase in efficacy. Intervention: The concomitant use of ibuprofen and famotidine with other NSAIDs or salicylates is not recommended. |
| Digoxin | drug interactions | Clinical Impact: The concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Intervention: During concomitant use of ibuprofen and famotidine and digoxin, monitor serum digoxin levels. |
| Erlotinib | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … on gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Fosamprenavir | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. Intervention: Concomitant administration of ibuprofen and famotidine is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. … |
| Furosemide | drug interactions | Diuretics Clinical Impact: Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. … Intervention: During concomitant use of ibuprofen and famotidine with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see … |
| Indomethacin | drug interactions | NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. |
| Itraconazole | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Ketoconazole | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Ledipasvir and sofosbuvir | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. Intervention: Concomitant administration of ibuprofen and famotidine is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. … |
Every other medicine the famotidine and ibuprofen label names
| Medicine named | Section | What the label says |
|---|---|---|
| Lithium | drug interactions | Clinical Impact: NSAIDs have produced elevations of plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. … Intervention: During concomitant use of ibuprofen and famotidine and lithium, monitor patients for signs of lithium toxicity. |
| Meloxicam | drug interactions | Pemetrexed Clinical Impact: Concomitant use of ibuprofen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … interaction between permetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following … |
| Methotrexate | drug interactions | Methotrexate Clinical Impact: Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (…). Intervention: During concomitant use of ibuprofen and famotidine and methotrexate, monitor patients for methotrexate toxicity. |
| Nabumetone | drug interactions | Pemetrexed Clinical Impact: Concomitant use of ibuprofen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). … interaction between permetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following … |
| Nilotinib | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Pemetrexed | drug interactions | Pemetrexed Clinical Impact: Concomitant use of ibuprofen and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (…). Intervention: During concomitant use of ibuprofen and famotidine and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI … |
| Propranolol | drug interactions | ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol). … Intervention: During concomitant use of ibuprofen and famotidine and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. … |
| Rilpivirine | drug interactions | Drugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine). |
| Tizanidine | drug interactions | Tizanidine (CYP1A2 Substrate) Clinical Impact: Famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Intervention: Avoid concomitant use with ibuprofen and famotidine. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine. |
| Warfarin | drug interactions | Drugs That Interfere with Hemostasis Clinical Impact: Ibuprofen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of ibuprofen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. … Intervention: Monitor patients with concomitant use of ibuprofen and famotidine with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin … |
Source: FDA drug label (Ibuprofen and famotidine), Aurobindo Pharma Limited, effective July 3, 2025 (SPL set 21688404-41fb-487e-8ba0-aea4431a42fa), via openFDA; the full label on DailyMed
What do FAERS reports show for famotidine and ibuprofen?
The FDA Adverse Event Reporting System holds 10 reports that list famotidine and ibuprofen among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 4 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as famotidine and ibuprofen?
20 other medicines are given the same way (oral) and in the same FDA class as famotidine and ibuprofen or labeled mainly for the same use (osteoarthritis), the same class first. Osteoarthritis lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Naproxen | Osteoarthritis, Rheumatoid arthritis | 146 labelers | $0.0565 per tablet 500 mg tablet | No current entry |
| Celecoxib | Osteoarthritis, Rheumatoid arthritis | 65 labelers | $0.0762 per capsule 200 mg capsule | No current entry |
| Diclofenac | Osteoarthritis, Rheumatoid arthritis | 67 labelers | $0.0619 per tablet 75 mg tablet | A presentation being discontinued |
| Meloxicam | Osteoarthritis, Rheumatoid arthritis | 43 labelers | $0.0166 per tablet 7.5 mg tablet | No current entry |
| Etodolac | Osteoarthritis, Rheumatoid arthritis | 30 labelers | $0.262 per tablet 400 mg tablet | No current entry |
| Indomethacin | Osteoarthritis, Rheumatoid arthritis | 25 labelers | $0.210 per capsule 75 mg capsule | No current entry |
| Nabumetone | Osteoarthritis, Rheumatoid arthritis | 28 labelers | $0.128 per tablet 500 mg tablet | No current entry |
| Diclofenac and misoprostol | Osteoarthritis, Rheumatoid arthritis | 10 labelers | $0.665 per tablet 50-0.2 mg tablet | No current entry |
Every medicine labeled for the same conditions as famotidine and ibuprofen
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to famotidine and ibuprofen
- 20 medicines for the same use
- Other H2 blockers
- the pharmacologic class, with prices and generics
- Famotidine and ibuprofen side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other